SARS-CoV-2 Specific Monoclonal Antibody for Post-COVID-19 Conditions (Long COVID)
SARS-CoV-2 Specific Monoclonal Antibody for Post-COVID-19 Conditions (Long COVID)
Recruiting · NCT07021794 · Registry updated 2026-09-29Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| SARS-CoV-2 Specific Monoclonal Antibody for Post-COVID-19 Conditions (Long COVID) | Actinomycetales infectious disease, Bacterial Infections and Mycoses, COVID-19, Chronic Disease, Coronaviridae Infections, Disease Attributes, Infections, Mycobacterium Infections, Nontuberculous, Nidovirales infectious disease, Orthocoronavirinae infectious disease, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Post-Infectious Disorders, RNA Virus Infections, bacterial infectious disease, gram-positive bacterial infections, long COVID-19, lung disorder, mycobacterial infectious disease, pneumonia, respiratory system disorder, respiratory tract infectious disorder, viral infectious disease, viral pneumonia | Recruiting | Phase 2 | 2026-09-29 | NCT07021794 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Florida Department of Health | 16 |
| Nancy Klimas | 1 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Nova Southeastern University | Fort Lauderdale | United States | 4 |